StockData
Rallybio Corp logo

Rallybio Corp (RLYB) stock

RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.29−0.14 (-0.88%)

Close on Nov 17, 2026Market cap $82.32MP/E 3.4Yield –

Rallybio r&d expenses

Research and development expenses are spending on new products and technology.

Rallybio's R&D Expenses for the twelve months ending Sep 30, 2026 was $7.87M, down 66.3% year over year. For fiscal 2025 it was $19.60M, down 52.8% from the year before. The highest annual figure on record is $53.54M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$19.60M-52.8%
FY2024Dec 31, 2024$41.51M-22.5%
FY2023Dec 31, 2023$53.54M+31.6%
FY2022Dec 31, 2022$40.69M+51.2%
FY2021Dec 31, 2021$26.91M+52.6%
FY2020Dec 31, 2020$17.63M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$584.00K-85.9%
Q2 FY2026Jun 30, 2026$758.00K-87.5%
Q1 FY2026Mar 31, 2026$2.87M-49.9%
Q4 FY2025Dec 31, 2025$3.66M-50.5%
Q3 FY2025Sep 30, 2025$4.14M-49.7%
Q2 FY2025Jun 30, 2025$6.07M-53.1%
Q1 FY2025Mar 31, 2025$5.73M-55.7%
Q4 FY2024Dec 31, 2024$7.39M-53.6%
Q3 FY2024Sep 30, 2024$8.24M-38.0%
Q2 FY2024Jun 30, 2024$12.95M-1.4%
Q1 FY2024Mar 31, 2024$12.94M+15.5%
Q4 FY2023Dec 31, 2023$15.92M+47.5%
Q3 FY2023Sep 30, 2023$13.29M+9.7%
Q2 FY2023Jun 30, 2023$13.13M+29.5%
Q1 FY2023Mar 31, 2023$11.20M+46.5%
Q4 FY2022Dec 31, 2022$10.79M+77.1%
Q3 FY2022Sep 30, 2022$12.11M+144.2%
Q2 FY2022Jun 30, 2022$10.14M+48.7%
Q1 FY2022Mar 31, 2022$7.65M-15.4%
Q4 FY2021Dec 31, 2021$6.09M-18.7%
Q3 FY2021Sep 30, 2021$4.96M-3.3%
Q2 FY2021Jun 30, 2021$6.82M+120.5%
Q1 FY2021Mar 31, 2021$9.04M–
Q4 FY2020Dec 31, 2020$7.50M–
Q3 FY2020Sep 30, 2020$5.13M–
Q2 FY2020Jun 30, 2020$3.09M–

More Rallybio figures

See a number that looks wrong?